+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system



Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system



Contraception 80(1): 84-89



The levonorgestrel-releasing intrauterine system (LNG-IUS) is a contraceptive method approved for five years of use. However, there is some evidence that its life span may be longer. The aim of the study was to evaluate serum levonorgestrel (LNG) and estradiol (E(2)) levels and endometrial thickness every 6 months from 7 to 8 1/2 years after insertion. At the end of the approved 5-year life span, no replacement devices were available; therefore, 86 women were allowed to retain the same device for a further 2 years. At the 7-year follow-up visit, the women who consented were again allowed to retain the same device for a further 18 months and were followed-up at six-monthly intervals. At each visit, vaginal sonography was performed to measure endometrial thickness, and a blood sample was taken to measure LNG and E(2). Eighty-four months after insertion, 67 women aged 34.3+/-0.8 years (mean+/-SEM) (range, 25-49 years) returned for follow-up. Mean+/-SEM LNG levels decreased from an initial 253+/-27 pg/mL (range, 86-760) during the first 2 months following insertion to 137+/-12 (range, 23-393) at 84 months and 119+/-9 pg/mL (range, 110-129) at 102 months of use (+/-SEM). At 84 months of use, mean+/-SEM endometrial thickness was 2.8+/-0.1 mm, increasing to 3.8+/-0.5 mm at 102 months of use. The incidence of amenorrhea decreased from 41.8% at 84 months to 31.5% at 102 months of use. No correlation was found between LNG levels and bleeding patterns; however, a weak correlation was found between high body mass index (kg/m(2)), high weight, and low serum LNG levels. E(2) levels were similar to those of the follicular phase of the menstrual cycle of regularly menstruating women. During extended use of the LNG-IUS, serum LNG levels were nearly half those found in the first 2 months of use (Wilcoxon signed rank test); serum E(2) levels were normal. Despite the very thin endometrium, menstrual bleeding was reinstated in many cases. At the end of its 5-year life span, there is a window for changing the LNG-IUS, and physicians and users should not be concerned about delaying replacement of the device for a short time beyond the approved life span; however, maintaining the same device long after its approved life span cannot be recommended.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055732389

Download citation: RISBibTeXText

PMID: 19501221

DOI: 10.1016/j.contraception.2009.01.004


Related references

Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 86(4): 345-349, 2013

Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstetrics and Gynecology 111(2 Pt 2): 547-549, 2008

Doses of levonorgestrel comparable to that delivered by the levonorgestrel-releasing intrauterine system can modify the in vitro expression of zona binding sites of human spermatozoa. Contraception 73(1): 97-101, 2005

Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertility and Sterility 83(2): 398-404, 2005

Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia. Nan Fang Yi Ke Da Xue Xue Bao 32(9): 1350-1354, 2013

Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia. Cochrane Database of Systematic Reviews 2013(6): Cd009458, 2013

Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecologic Oncology 95(3): 762-764, 2004

Endometrial Synovial-like Metaplasia Associated With Levonorgestrel-releasing Intrauterine System. International Journal of Gynecological Pathology 34(6): 570-575, 2016

Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstetrics and Gynecology 77(2): 261-264, 1991

Endometrial adenocarcinoma in association with a levonorgestrel-releasing intrauterine system (Mirena). Journal of Family Planning and Reproductive Health Care 32(2): 113-114, 2006

Levonorgestrel-releasing intrauterine system vs. endometrial thermal ablation for menorrhagia. Hormones 8(1): 60-64, 2009

Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstetrical and Gynecological Survey 67(11): 726-733, 2013

Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. American Journal of Obstetrics & Gynecology 188(5): 1297-1298, 2003

Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstetricia et Gynecologica Scandinavica 82(6): 580-582, 2003

Levonorgestrel-Releasing Intrauterine System vs. Oral Progestins for Treatment of Endometrial Hyperplasia. American Family Physician 93(11): 948-949, 2017